FDA acceptance of bezuclastinib NDA puts Cogent Biosciences in focus
Cogent Biosciences (COGT) is back on investors' radar after the FDA accepted its New Drug Application for bezuclastinib in Gastrointestinal Stromal Tumors under the Real-Time Oncology Review program.
The filing follows results from the Phase 3 PEAK trial, in which bezuclastinib combined with sunitinib reduced the risk of disease progression or death by 50% compared with sunitinib alone and received Breakthrough Therapy Designation.
See our latest analysis for Cogent Biosciences.
The FDA acceptance has arrived after a huge re-rating in Cogent Biosciences, with the latest share price at $35.21, a modest 1-day share price decline of 0.09% and a 30-day share price return of 6.01% in the red. The 1-year total shareholder return is very large and the 3-year total shareholder return is more than triple, suggesting momentum has cooled recently but remains strong over a longer horizon.
If you are tracking how clinical milestones can move early stage names, it may also be worth looking at other AI driven healthcare opportunities through this 36 healthcare AI stocks
With Cogent Biosciences now valued at about US$5.7b and trading at US$35.21 after a 30 day return of 6.01% in the red, is this an underappreciated drug story, or a stock that already reflects future growth?
Preferred Price to Book of 10.4x: Is it justified?
At a last close of $35.21 and a market cap of about $5.7b, Cogent Biosciences is trading on a P/B of 10.4x, which sits well above the broader US Biotechs industry but below its closer peer group.
P/B compares the share price with the company’s net assets on the balance sheet. A 10.4x reading means investors are paying more than ten times book value for a business that is still loss making, with net income at a loss of $328.9m and revenue below $1m. For an early stage biotech with minimal current revenue, a higher P/B often reflects expectations around the pipeline, clinical data and potential future cash flows rather than today’s earnings.
Relative to the wider US Biotechs industry average P/B of 2.3x, Cogent’s 10.4x looks expensive, which suggests the market is assigning a much richer value to its assets than to the typical biotech peer. However, when compared with its more direct peer set, where the average P/B is 27.7x, Cogent sits at a discount, implying investors are pricing it more conservatively than some high multiple comparables even after the recent re rating.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Preferred multiple of Price-to-Book of 10.4x (ABOUT RIGHT)
However, the story still faces real pressure points, including a US$328.9m net loss, zero reported revenue, and binary outcomes around late stage trial and FDA decisions.
Find out about the key risks to this Cogent Biosciences narrative.
Next Steps
Does this feel like a story tilted more to risk or reward? If you want to move fast and make up your own mind, start by weighing the 1 key reward and 2 important warning signs
Looking for more investment ideas?
If you are serious about building a stronger portfolio, do not stop at one stock. Use broad, rules based screens to uncover ideas you might otherwise miss.
- Target potential mispricings by scanning for companies that combine strong fundamentals with lower valuations through the 59 high quality undervalued stocks.
- Strengthen your income stream by focusing on businesses with robust payouts using the 13 dividend fortresses.
- Prioritize resilience by filtering for companies with healthier finances through the solid balance sheet and fundamentals stocks screener (40 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com